The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications

Can J Cardiol. 2015 Jan;31(1):3-16. doi: 10.1016/j.cjca.2014.10.022. Epub 2014 Dec 19.


The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Update provides discussion on the management recommendations on 3 focused areas: (1) anemia; (2) biomarkers, especially natriuretic peptides; and (3) clinical trials that might change practice in the management of patients with heart failure. First, all patients with heart failure and anemia should be investigated for reversible causes of anemia. Second, patients with chronic stable heart failure should undergo natriuretic peptide testing. Third, considerations should be given to treat selected patients with heart failure and preserved systolic function with a mineralocorticoid receptor antagonist and to treat patients with heart failure and reduced ejection fraction with an angiotensin receptor/neprilysin inhibitor, when the drug is approved. As with updates in previous years, the topics were chosen in response to stakeholder feedback. The 2014 Update includes recommendations, values and preferences, and practical tips to assist the clinicians and health care workers to best manage patients with heart failure.

Publication types

  • Practice Guideline

MeSH terms

  • Anemia / blood
  • Anemia / prevention & control*
  • Angiotensin Receptor Antagonists / therapeutic use
  • Biomarkers / blood*
  • Blood Pressure
  • Canada
  • Cardiology / organization & administration*
  • Clinical Trials as Topic
  • Heart Failure / blood
  • Heart Failure / diagnosis*
  • Heart Failure / drug therapy
  • Humans
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Neprilysin / antagonists & inhibitors
  • Societies, Medical / organization & administration*


  • Angiotensin Receptor Antagonists
  • Biomarkers
  • Mineralocorticoid Receptor Antagonists
  • Neprilysin